Jiangsu Changyou Environmental Protection Technology
301557
Hefei conver Holding
603409
LIERDA
832149
4
SHENGNAN TECHNOLOGY
837006
5
CHK
831167
CN Stock MarketDetailed Quotes
002581 Shandong Sinobioway Biomedicine
- 10.31
- -0.11-1.06%
Market Closed Mar 4 15:00 CST
6.80BMarket Cap-19.56P/E (TTM)
10.50High10.11Low183.91KlotVolume10.25Open10.42Pre Close188.84MTurnover4.59%Turnover RatioLossP/E (Static)659.74MShares14.4352wk High3.25P/B4.13BFloat Cap7.7952wk Low11.46Limit Up400.79MShs Float71.85Historical High9.38Limit Down3.74%Amplitude4.39Historical Low--Dividend TTM10.27Avg Price99.89KlotAsk--Div YieldTTM100Lot Size80.04KlotBid
Shandong Sinobioway Biomedicine News
Unnamed Pharmaceuticals: Announcement on the completion of the 2024 Stock Option Incentive Plan grant
Unnamed Pharmaceuticals: Announcement on Granting Stock Options to Incentive Recipients of the Company\'s 2024 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Supervisory Board\'s Review Opinions on the List of Incentive Recipients Granted by the Company\'s 2024 Stock Option Incentive Plan
Unnamed Medicine: Legal Opinion of Zhejiang Tianzu (Shenzhen) Law Firm on the awarding of the 2024 Stock Option Incentive Plan for Shandong Weiming Biomedical Co., Ltd.
Unnamed Pharmaceuticals: Self-inspection Report on the 2024 Stock Options Incentive Plan: Insider Information Insiders and Incentive Targets to Trade Company Shares
Unnamed Pharmaceuticals: Explanation and Verification Opinions of the Supervisory Board on the Publication of the Company\'s 2024 Stock Option Incentive Plan Incentive List
Unnamed Pharmaceuticals: Announcement on the progress of the transfer of shares in participating companies through public listing
Unnamed Pharmaceuticals: An indicative announcement on the adoption of an autonomous exercise model during the first exercise period of the 2023 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Shandong Weiming Biomedical Co., Ltd. 2024 Stock Option Incentive Plan Implementation Assessment Measures
Unnamed Pharmaceutical: Notice on requesting the shareholders\' meeting to authorize the board of directors to handle matters relating to the company\'s 2024 stock option incentive plan
Unnamed Medicine: Legal Opinion of Zhejiang Tianzu (Shenzhen) Law Firm on Shandong Weiming Biomedical Co., Ltd. 2024 Stock Option Incentive Plan (Draft)
Unnamed Pharmaceuticals: Supervisory Board\'s Review Opinions on Matters Related to the 2024 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Draft Equity Incentive Plan Self-Inspection Form
Unnamed Pharmaceuticals: Shandong Weiming Biomedical Co., Ltd. 2024 Stock Option Incentive Plan Draft (Summary)
Weiming Pharmaceutical: Shandong Weiming Biomedical Co., Ltd. 2024 Stock Option Incentive Plan (Draft)
Unnamed Pharmaceuticals: 2024 Stock Option Incentive Plan Incentive List
Unnamed Pharmaceuticals: Announcement on the progress of the transfer of shares in participating companies through public listing
Unnamed Pharmaceuticals: 2024-053 Announcement on the progress of the proposed transfer of shares in participating companies through public listing
Unnamed Pharmaceuticals: Announcement on the completion of cancellation of some stock options in the 2023 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Announcement on the progress of the proposed transfer of shares in participating companies through public listing